Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

MEZZANINE EQUITY (Details Narrative)

MEZZANINE EQUITY (Details Narrative) - USD ($)		3 Months Ended				9 Months Ended
MEZZANINE EQUITY (Details Narrative) - USD ($)	Jan. 10, 2020	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Oct. 10, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Preferred stock aggregate purchase price
Preferred stock liquidation preference		$ 6.00				$ 6.00
Proceeds from underwriting discount and commission						$ 25,000,000
Common Stock [Member]
Class of Stock [Line Items]
Preferred stock aggregate purchase price			$ 1,000
Aggregate of shares issued		45,834	39,668	16,666	22,996
Reserve stock split						7,833,334
Sale of stock price per share		$ 12.00				$ 12.00
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Aggregate of shares issued	27,000
Preferred stock conversion price per share	$ 6.00
Maximum preferred stock holders rights percentage						The Series B Certificate of Designation also provides each Investor with the following director designation rights: for so long such Investor holds at least sixty percent (60%) of the Series B Preferred Stock issued to it on the Issuance Date (as defined therein), such Investor will be entitled to elect two directors to the Company’s Board of Directors (the “Board”), provided that one of the directors qualifies as an “independent director” under Rule 5605(a)(2) of the listing rules of the Nasdaq Stock Market (or any successor rule or similar rule promulgated by another exchange on which the Company’s securities are then listed or designated) (“Independent Director”). However, if at any time such Investor holds less than sixty percent (60%), but at least forty percent (40%), of the Series B Preferred Stock issued to them on the Issuance Date, such Investor would only be entitled to elect one director to the Board. Any director elected pursuant to the terms of the Series B Certificate of Designation may be removed without cause by, and only by, the affirmative vote of the holders of Series B Preferred Stock. A vacancy in any directorship filled by the holders of Series B Preferred Stock may be filled only by vote or written consent in lieu of a meeting of such holders of Series B Preferred Stock or by any remaining director or directors elected by such holders of Series B Preferred Stock.
Temporary equity shares issued		47,000				47,000		47,000
Temporary equity shares outstanding		47,000				47,000		47,000
Series B Preferred Stock [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Preferred stock par value per share							$ 0.01
Preferred stock conversion price per share							6.00
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Aggregate of shares issued	270
Value of preferred stock exchanged	$ 27,000,000.0
Preferred stock par value per share	$ 0.01
Preferred shares stated value per share	$ 100,000
Preferred stock shares authorized	0
Preferred stock shares issued	0
Preferred stock shares outstanding	0
Series C Preferred Stock [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Preferred stock par value per share							0.01
Preferred stock conversion price per share							$ 2.02
Security Purchase and Exchange Agreement [Member] \| Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock aggregate purchase price	$ 20,000,000.0
Issuance price per preferred stock	$ 1,000
Security Purchase and Exchange Agreement [Member] \| Series B Preferred Stock [Member] \| 1315 Capital [Member]
Class of Stock [Line Items]
Preferred stock aggregate purchase price	$ 19,000,000.0
Aggregate of shares issued	19,000
Security Purchase and Exchange Agreement [Member] \| Series B Preferred Stock [Member] \| Ampersand Limited Partners [Member]
Class of Stock [Line Items]
Preferred stock aggregate purchase price	$ 1,000,000.0
Aggregate of shares issued	1,000